A randomized, controlled, multicenter phase III clinical trial of Huo Xiang Zheng Qi oral liquid for the prevention and control of nausea and vomiting caused by multiday cisplatin-based regimen
HXZQ in combination with a 5-HT3 receptor antagonist and dexamethasone is safe and feasible for preventing CINV due to 3-day cisplatin-containing HEC throughout the whole cycle.
Authors
- Jie Xian
- Zengjin Hu
- Z.M. Ye
- Songze Wu (ORCID: https://orcid.org/0000-0001-5065-8511)
- Taifang Peng
- Xianguo Liu (ORCID: https://orcid.org/0000-0003-2034-5578)
- Jiang Zhu (ORCID: https://orcid.org/0000-0002-2601-4967)
- Yanan Sun (ORCID: https://orcid.org/0000-0003-4940-3743)
- N Li
- Zhiying Yue (ORCID: https://orcid.org/0009-0007-6777-3488)
- Ying Wang (ORCID: https://orcid.org/0000-0003-2121-7025)
- Ting Li (ORCID: https://orcid.org/0000-0002-2027-9462)
- Juan Chen
- Jun He
- Liqin Xia
- Yangang Zhou
- Lang He
- Liping Tong
Institutions
- Sichuan University (CN)
- Affiliated Hospital of Southwest Medical University (CN)
- West China Hospital of Sichuan University (CN)
- Suizhou Central Hospital (CN)
- Qianjiang Central Hospital (CN)
- Sichuan Cancer Hospital (CN)
- First Affiliated Hospital of Chengdu Medical College (CN)
- Chengdu Fifth People's Hospital (CN)
- Second People’s Hospital of Yibin (CN)
Publication Details
- Journal
- Medicine
- Published
- 2025-12-26
- DOI
- https://doi.org/10.1097/md.0000000000046778
- Primary Topic
- Nausea and vomiting management
- Type
- article
- Field-Weighted Citation Impact
- 0.00